Recommended Liver Monitoring for Kisqali
Kisqali (ribociclib) requires baseline liver function tests before starting treatment, including serum transaminases (ALT and AST) and bilirubin. Repeat tests occur every 2 weeks for the first 2 cycles, then at the beginning of each subsequent cycle, and as clinically indicated.[1][2]
Why Monitor Liver Enzymes?
Kisqali can cause elevated transaminases, seen in up to 10% of patients with ALT/AST increases above 5 times the upper limit of normal (ULN). Severe cases (grade 3/4) occur in about 6-8% of patients, sometimes with concurrent bilirubin elevation, leading to hepatotoxicity. Monitoring detects early changes to allow dose interruptions or reductions.[1][2]
What to Do If Abnormalities Occur
- For ALT/AST >3x ULN with total bilirubin ≤2x ULN (grade 2), continue at current dose but monitor more frequently.
- For ALT/AST >3x ULN with total bilirubin >2x ULN, or >5x ULN alone (grade 3/4), interrupt until recovery to ≤2.5x ULN, then resume at a reduced dose.
- Permanent discontinuation if confirmed hepatotoxicity or recurrence at lower doses.
Dose adjustments follow specific tables based on severity.[1][2]
How Does This Compare to Other CDK4/6 Inhibitors?
Verzenio (abemaciclib) requires baseline tests and monitoring every 2-3 weeks initially, but continues monthly thereafter, with similar thresholds for interruption. Ibrance (palbociclib) monitors at baseline, cycle 1 day 15, and then monthly, with less frequent early checks than Kisqali. All share hepatotoxicity risks but differ in schedules.[2][3]
Patient Factors Affecting Monitoring
Increase frequency in patients with baseline liver impairment (Child-Pugh B/C), concomitant hepatotoxic drugs (e.g., statins), or comorbidities like hepatitis. No routine imaging unless symptoms (jaundice, fatigue) suggest issues.[1][2]
Sources
[1]: Kisqali Prescribing Information (Novartis)
[2]: FDA Label for Ribociclib
[3]: NCCN Guidelines Breast Cancer (v. 5.2024)